Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12114MR)

This product GTTS-WQ12114MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12114MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2633MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ6557MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ3336MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ1776MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ1107MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ13126MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ7955MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ12529MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW